• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-A12B filed by Cencora Inc.

    5/22/25 4:06:45 PM ET
    $COR
    Other Pharmaceuticals
    Health Care
    Get the next $COR alert in real time by email
    8-A12B 1 tm2515854d2_8a12b.htm 8-A12B

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-A

     

     

     

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
    PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

     

     

     

    Cencora, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

     

    Delaware 23-3079390
    (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.)
       
    1 West First Avenue  
    Conshohocken, PA 19428-1800
    (Address of Principal Executive Offices) (Zip Code)

     

    Title of Each Class 
    to be Registered

    2.875% Senior Notes due 2028

    3.625% Senior Notes due 2032

    Name of Each Exchange on Which
    Each Class is to be Registered

    New York Stock Exchange
    New York Stock Exchange

     

     

     

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. x

     

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ¨

     

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ¨

     

    Securities Act registration statement file number to which this form relates:

    333-283481

    (if applicable)

     

    Securities to be registered pursuant to Section 12(g) of the Act:

    None

     

     

     

     

     

     

    Item 1. Description of Registrant's Securities to be Registered.

     

    The titles of the securities to be registered hereunder are “2.875% Senior Notes due 2028” and “3.625% Senior Notes due 2032” (collectively, the “Notes”). For a description of the securities to be registered hereunder, reference is made to the information under the heading “Description of Notes” in the prospectus supplement, dated May 15, 2025, which was filed with the Securities and Exchange Commission (the “Commission”) on May 19, 2025, pursuant to Rule 424(b)(2) under the Securities Act of 1933, and under the heading “Description of Debt Securities” in the prospectus, dated November 26, 2024, contained in our effective registration statement on Form S-3 (Registration No. 333-283481), which registration statement was filed with the Commission on November 26, 2024, which information is incorporated herein by reference and made part of this registration statement in its entirety.

     

    Item 2. Exhibits.

     

    Exhibit 
    Number
    Description
    4.1 Indenture, dated as of November 19, 2009, between Cencora, Inc. and U.S. Bank National Association (as successor-in-interest to U.S. Bank National Association), as Trustee (incorporated by reference to Exhibit 4.1 to the Registrant's Current Report on Form 8-K filed on November 23, 2009).
       
    4.2   Sixteenth Supplemental Indenture dated as of May 22, 2025 by and among Cencora, Inc., U.S. Bank Trust Company, National Association, as Trustee, and U.S. Bank Europe DAC, UK Branch, as Paying Agent (including Form of 2.875% Senior Note due 2028) (incorporated herein by reference to Exhibit 4.1 to the Current Report on Form 8-K dated May 22, 2025 and filed on May 22, 2025).  
       
    4.3   Seventeenth Supplemental Indenture dated as of May 22, 2025 by and among Cencora, Inc., U.S. Bank Trust Company, National Association, as Trustee, and U.S. Bank Europe DAC, UK Branch, as Paying Agent (including Form of 3.625% Senior Note due 2032) (incorporated herein by reference to Exhibit 4.2 to the Current Report on Form 8-K dated May 22, 2025 and filed on May 22, 2025).  

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

     

      Cencora, Inc.
       
    May 22, 2025 By: /s/ James F. Cleary
        Name: James F. Cleary
        Title: Executive Vice President and Chief Financial Officer

     

     

     

    Get the next $COR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $COR

    DatePrice TargetRatingAnalyst
    6/3/2025$337.00Equal Weight → Overweight
    Wells Fargo
    12/4/2024$280.00Outperform
    Mizuho
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    2/26/2024$261.00Outperform
    Leerink Partners
    1/3/2024$242.00Overweight
    Barclays
    12/14/2023$213.00Equal Weight
    Wells Fargo
    12/14/2021$162.00 → $170.00Buy → Neutral
    Citigroup
    11/26/2021$136.00 → $170.00Sector Perform
    RBC Capital
    More analyst ratings

    $COR
    SEC Filings

    See more
    • Cencora Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Cencora, Inc. (0001140859) (Filer)

      7/3/25 4:01:37 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form 11-K filed by Cencora Inc.

      11-K - Cencora, Inc. (0001140859) (Filer)

      6/17/25 4:33:24 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Cencora, Inc. (0001140859) (Filer)

      6/6/25 4:01:51 PM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cencora upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Cencora from Equal Weight to Overweight and set a new price target of $337.00

      6/3/25 7:24:57 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Mizuho resumed coverage on Cencora with a new price target

      Mizuho resumed coverage of Cencora with a rating of Outperform and set a new price target of $280.00

      12/4/24 7:30:44 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora downgraded by BofA Securities with a new price target

      BofA Securities downgraded Cencora from Buy to Neutral and set a new price target of $245.00 from $275.00 previously

      9/18/24 8:27:47 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Vice President Campbell Elizabeth S was granted 46 shares, increasing direct ownership by 0.31% to 14,710 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      7/7/25 4:44:50 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Executive Vice President Battaglia Silvana was granted 53 shares, increasing direct ownership by 0.47% to 11,349 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      7/7/25 4:02:37 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Director Ryerkerk Lori was granted 516 shares (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      7/2/25 4:01:11 PM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 6, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the c

      7/3/25 7:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Elects Lori J. Ryerkerk to Its Board of Directors

      Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. "Ms. Ryerkerk's experience in complex, global supply chains will further strengthen the Board's expertise as we continue supporting the company's long-term growth. Her appointment reflects the Cencora Board's ongoing commitment to leaders who can help us contribute to driving stakeholder value," said Mark Durcan, Lead Independent Director. "Lori's experience as a public company CEO, leading a global specialties chemical company with extensive operations and logistics, will bring valuable insight as we execute against our strategy and bu

      5/28/25 7:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Reports Fiscal 2025 Second Quarter Results

      Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

      5/7/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Durcan Dermot Mark bought $109,290 worth of shares (500 units at $218.58), increasing direct ownership by 2% to 21,876 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/29/24 4:02:27 PM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Leadership Updates

    Live Leadership Updates

    See more
    • Cencora Expands Enterprise Leadership Team with Two Senior Appointments

      Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

      11/4/24 8:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Network Wireless Solutions (NWS) Appoints Michael Millegan to Board of Directors

      The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo

      9/14/21 2:00:00 PM ET
      $AXS
      $COR
      $POR
      $WTT
      Property-Casualty Insurers
      Finance
      Other Pharmaceuticals
      Health Care

    $COR
    Financials

    Live finance-specific insights

    See more
    • Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 6, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the c

      7/3/25 7:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Reports Fiscal 2025 Second Quarter Results

      Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

      5/7/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via

      3/28/25 7:00:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cencora Inc.

      SC 13G/A - Cencora, Inc. (0001140859) (Subject)

      11/14/24 1:22:34 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cencora Inc.

      SC 13D/A - Cencora, Inc. (0001140859) (Subject)

      8/5/24 6:43:49 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by CoreSite Realty Corporation (Amendment)

      SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)

      7/12/21 8:29:18 AM ET
      $COR
      Other Pharmaceuticals
      Health Care